{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T07:11:50Z","timestamp":1784358710751,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-13811-9","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T15:34:04Z","timestamp":1754321644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Synchronous surgery combined preoperative chemotherapy benefits patients suffering pancreatic ductal adenocarcinoma with liver metastases: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Pengcheng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bole","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"13811_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348. https:\/\/doi.org\/10.3322\/caac.21763 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"13811_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","volume":"16","author":"O Strobel","year":"2019","unstructured":"Strobel, O., Neoptolemos, J., J\u00e4ger, D. & B\u00fcchler, M. W. Optimizing the outcomes of pancreatic cancer surgery. Nat. Rev. Clin. Oncol. 16, 11\u201326. https:\/\/doi.org\/10.1038\/s41571-018-0112-1 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"13811_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12957-024-03310-y","volume":"22","author":"C Liu","year":"2024","unstructured":"Liu, C. et al. Association between preoperative sarcopenia and prognosis of pancreatic cancer after curative-intent surgery: A updated systematic review and meta-analysis. World J. Surg. Oncol. 22, 38. https:\/\/doi.org\/10.1186\/s12957-024-03310-y (2024).","journal-title":"World J. Surg. Oncol."},{"key":"13811_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park, W., Chawla, A. & O\u2019Reilly, E. M. Pancreatic cancer: A review. JAMA 326, 851\u2013862. https:\/\/doi.org\/10.1001\/jama.2021.13027 (2021).","journal-title":"JAMA"},{"key":"13811_CR5","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/s0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi, J. D., Surana, R., Valle, J. W. & Shroff, R. T. Pancreatic cancer. Lancet 395, 2008\u20132020. https:\/\/doi.org\/10.1016\/s0140-6736(20)30974-0 (2020).","journal-title":"Lancet"},{"key":"13811_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/jhbp.1026","volume":"29","author":"T Sakaguchi","year":"2022","unstructured":"Sakaguchi, T. et al. A simple risk score for detecting radiological occult metastasis in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma. J. Hepatobiliary Pancreat. Sci. 29, 262\u2013270. https:\/\/doi.org\/10.1002\/jhbp.1026 (2022).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"13811_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s00330-020-07115-x","volume":"31","author":"Y Noda","year":"2021","unstructured":"Noda, Y., Tochigi, T., Baliyan, V., Kordbacheh, H. & Kambadakone, A. Hepatobiliary contrast uptake patterns on gadoxetic acid-enhanced MRI in liver metastases from pancreatic ductal adenocarcinoma: Can it predict prognosis?. Eur. Radiol. 31, 276\u2013282. https:\/\/doi.org\/10.1007\/s00330-020-07115-x (2021).","journal-title":"Eur. Radiol."},{"key":"13811_CR8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/1120009x.2022.2026125","volume":"34","author":"S Ay","year":"2022","unstructured":"Ay, S. et al. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer. J. Chemother. 34, 465\u2013471. https:\/\/doi.org\/10.1080\/1120009x.2022.2026125 (2022).","journal-title":"J. Chemother."},{"key":"13811_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020416","author":"F Di Costanzo","year":"2023","unstructured":"Di Costanzo, F., Di Costanzo, F., Antonuzzo, L., Mazza, E. & Giommoni, E. Optimizing first-line chemotherapy in metastatic pancreatic cancer: Efficacy of FOLFIRINOX versus nab-paclitaxel plus gemcitabine. Cancers https:\/\/doi.org\/10.3390\/cancers15020416 (2023).","journal-title":"Cancers"},{"key":"13811_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s13304-020-00710-z","volume":"72","author":"S Crippa","year":"2020","unstructured":"Crippa, S. et al. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates Surg. 72, 39\u201345. https:\/\/doi.org\/10.1007\/s13304-020-00710-z (2020).","journal-title":"Updates Surg."},{"key":"13811_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113402","author":"O De Simoni","year":"2020","unstructured":"De Simoni, O. et al. Oligometastatic pancreatic cancer to the liver in the era of neoadjuvant chemotherapy: Which role for conversion surgery? A systematic review and meta-analysis. Cancers https:\/\/doi.org\/10.3390\/cancers12113402 (2020).","journal-title":"Cancers"},{"key":"13811_CR12","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.pan.2019.05.466","volume":"19","author":"T Sakaguchi","year":"2019","unstructured":"Sakaguchi, T., Valente, R., Tanaka, K., Satoi, S. & Del Chiaro, M. Surgical treatment of metastatic pancreatic ductal adenocarcinoma: A review of current literature. Pancreatology 19, 672\u2013680. https:\/\/doi.org\/10.1016\/j.pan.2019.05.466 (2019).","journal-title":"Pancreatology"},{"key":"13811_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int. J. Surg. 88, 105906. https:\/\/doi.org\/10.1016\/j.ijsu.2021.105906 (2021).","journal-title":"Int. J. Surg."},{"key":"13811_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea, B. J. et al. AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 358, j4008. https:\/\/doi.org\/10.1136\/bmj.j4008 (2017).","journal-title":"BMJ"},{"key":"13811_CR15","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup, D. F. et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283, 2008\u20132012. https:\/\/doi.org\/10.1001\/jama.283.15.2008 (2000).","journal-title":"JAMA"},{"key":"13811_CR16","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.21037\/jgo-23-655","volume":"14","author":"S Satoi","year":"2023","unstructured":"Satoi, S. et al. Oncological role of surgical resection in patients with pancreatic ductal adenocarcinoma with liver-only synchronous metastases in a single-center retrospective study. J. Gastrointest. Oncol. 14, 2587\u20132599. https:\/\/doi.org\/10.21037\/jgo-23-655 (2023).","journal-title":"J. Gastrointest. Oncol."},{"key":"13811_CR17","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/jhbp.1303","volume":"30","author":"M Nagai","year":"2023","unstructured":"Nagai, M. et al. Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients. J. Hepatobiliary Pancreat. Sci. 30, 1025\u20131035. https:\/\/doi.org\/10.1002\/jhbp.1303 (2023).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"13811_CR18","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/jhbp.1313","volume":"30","author":"WG Yun","year":"2023","unstructured":"Yun, W. G. et al. The role of local treatment including pancreatectomy for pancreatic ductal adenocarcinoma patients with isolated synchronous liver metastasis: Propensity score-matched analyses. J. Hepatobiliary Pancreat. Sci. 30, 1036\u20131045. https:\/\/doi.org\/10.1002\/jhbp.1313 (2023).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"13811_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.surg.2022.03.003","volume":"172","author":"P Bachellier","year":"2022","unstructured":"Bachellier, P., Addeo, P., Averous, G. & Dufour, P. Resection of pancreatic adenocarcinomas with synchronous liver metastases: A retrospective study of prognostic factors for survival. Surgery 172, 1245\u20131250. https:\/\/doi.org\/10.1016\/j.surg.2022.03.003 (2022).","journal-title":"Surgery"},{"issue":"3","key":"13811_CR20","first-page":"622","volume":"38","author":"T Jin","year":"2022","unstructured":"Jin, T., Dai, C. & Xu, F. Clinical effect of simultaneous surgical resection of hepatic and pancreatic lesions versus systemic chemotherapy in treatment of resectable pancreatic cancer with liver metastasis. J. Clin. Hepatol. 38(3), 622\u2013628 (2022).","journal-title":"J. Clin. Hepatol."},{"key":"13811_CR21","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1007\/s10147-021-01961-5","volume":"26","author":"SA Safi","year":"2021","unstructured":"Safi, S. A. et al. Surgical margin clearance and extended chemotherapy defines survival for synchronous oligometastatic liver lesions of the ductal adenocarcinoma of the pancreas. Int. J. Clin. Oncol. 26, 1911\u20131921. https:\/\/doi.org\/10.1007\/s10147-021-01961-5 (2021).","journal-title":"Int. J. Clin. Oncol."},{"key":"13811_CR22","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.amsu.2020.11.037","volume":"62","author":"Y Shao","year":"2021","unstructured":"Shao, Y. et al. Feasibility of pancreaticoduodenectomy with synchronous liver metastasectomy for oligometastatic pancreatic ductal adenocarcinoma: A case-control study. Ann. Med. Surg. 62, 490\u2013494. https:\/\/doi.org\/10.1016\/j.amsu.2020.11.037 (2021).","journal-title":"Ann. Med. Surg."},{"key":"13811_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.hpb.2019.05.015","volume":"22","author":"J Yang","year":"2020","unstructured":"Yang, J. et al. Patients with hepatic oligometastatic pancreatic body\/tail ductal adenocarcinoma may benefit from synchronous resection. HPB 22, 91\u2013101. https:\/\/doi.org\/10.1016\/j.hpb.2019.05.015 (2020).","journal-title":"HPB"},{"key":"13811_CR24","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.suronc.2018.09.004","volume":"27","author":"A Andreou","year":"2018","unstructured":"Andreou, A. et al. The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. Surg. Oncol. 27, 688\u2013694. https:\/\/doi.org\/10.1016\/j.suronc.2018.09.004 (2018).","journal-title":"Surg. Oncol."},{"key":"13811_CR25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ejso.2016.10.023","volume":"43","author":"T Hackert","year":"2017","unstructured":"Hackert, T. et al. Radical surgery of oligometastatic pancreatic cancer. Eur. J. Surg. Oncol. 43, 358\u2013363. https:\/\/doi.org\/10.1016\/j.ejso.2016.10.023 (2017).","journal-title":"Eur. J. Surg. Oncol."},{"key":"13811_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.surg.2016.02.019","volume":"160","author":"M Tachezy","year":"2016","unstructured":"Tachezy, M. et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery 160, 136\u2013144. https:\/\/doi.org\/10.1016\/j.surg.2016.02.019 (2016).","journal-title":"Surgery"},{"key":"13811_CR27","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.ejso.2016.06.398","volume":"42","author":"S Crippa","year":"2016","unstructured":"Crippa, S. et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?. Eur. J. Surg. Oncol. 42, 1533\u20131539. https:\/\/doi.org\/10.1016\/j.ejso.2016.06.398 (2016).","journal-title":"Eur. J. Surg. Oncol."},{"key":"13811_CR28","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1002\/cncr.23074","volume":"110","author":"AL Gleisner","year":"2007","unstructured":"Gleisner, A. L. et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?. Cancer 110, 2484\u20132492. https:\/\/doi.org\/10.1002\/cncr.23074 (2007).","journal-title":"Cancer"},{"key":"13811_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1245\/s10434-006-9131-8","volume":"14","author":"SV Shrikhande","year":"2007","unstructured":"Shrikhande, S. V. et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann. Surg. Oncol. 14, 118\u2013127. https:\/\/doi.org\/10.1245\/s10434-006-9131-8 (2007).","journal-title":"Ann. Surg. Oncol."},{"key":"13811_CR30","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.3390\/curroncol30050340","volume":"30","author":"K Tepelenis","year":"2023","unstructured":"Tepelenis, K. et al. The role of preoperative chemotherapy in the management of synchronous resectable colorectal liver metastases: A meta-analysis. Curr. Oncol. 30, 4499\u20134511. https:\/\/doi.org\/10.3390\/curroncol30050340 (2023).","journal-title":"Curr. Oncol."},{"key":"13811_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s40001-022-00937-z","volume":"27","author":"SH Wang","year":"2022","unstructured":"Wang, S. H., Song, L., Tang, J. Y., Sun, W. P. & Li, Z. Safety and long-term prognosis of simultaneous versus staged resection in synchronous colorectal cancer with liver metastasis: A systematic review and meta-analysis. Eur. J. Med. Res. 27, 297. https:\/\/doi.org\/10.1186\/s40001-022-00937-z (2022).","journal-title":"Eur. J. Med. Res."},{"key":"13811_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.993524","volume":"12","author":"Z Wu","year":"2022","unstructured":"Wu, Z., Qiu, X., Zhi, Y., Shi, X. & Lv, G. The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database. Front. Oncol. 12, 993524. https:\/\/doi.org\/10.3389\/fonc.2022.993524 (2022).","journal-title":"Front. Oncol."},{"key":"13811_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.903560","volume":"12","author":"Z Yang","year":"2022","unstructured":"Yang, Z., Liang, J., Leng, K. & Shi, G. Survival benefit of surgical resection for pancreatic neuroendocrine tumors with oligometastatic liver metastasis: A retrospective and propensity score-matching analysis. Front. Oncol. 12, 903560. https:\/\/doi.org\/10.3389\/fonc.2022.903560 (2022).","journal-title":"Front. Oncol."},{"key":"13811_CR34","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1002\/cam4.2431","volume":"8","author":"M Zheng","year":"2019","unstructured":"Zheng, M., Li, Y., Li, T., Zhang, L. & Zhou, L. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis. Cancer Med. 8, 5128\u20135136. https:\/\/doi.org\/10.1002\/cam4.2431 (2019).","journal-title":"Cancer Med."},{"key":"13811_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jhbp.1184","volume":"30","author":"T Takeda","year":"2023","unstructured":"Takeda, T. et al. Outcomes of pancreatic cancer with liver oligometastasis. J. Hepatobiliary Pancreat. Sci. 30, 229\u2013239. https:\/\/doi.org\/10.1002\/jhbp.1184 (2023).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"13811_CR36","first-page":"567","volume":"44","author":"T Takada","year":"1997","unstructured":"Takada, T., Yasuda, H., Amano, H., Yoshida, M. & Uchida, T. Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: does it improve survival?. Hepatogastroenterology 44, 567\u2013573 (1997).","journal-title":"Hepatogastroenterology"},{"key":"13811_CR37","doi-asserted-by":"publisher","first-page":"361","DOI":"10.6092\/1590-8577\/963","volume":"13","author":"KS Gunturu","year":"2012","unstructured":"Gunturu, K. S., Jarboe, J. & Saif, M. W. Highlights on the first line treatment of metastatic pancreatic cancer. Jop 13, 361\u2013367. https:\/\/doi.org\/10.6092\/1590-8577\/963 (2012).","journal-title":"Jop"},{"key":"13811_CR38","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369 (2013).","journal-title":"N. Engl. J. Med."},{"key":"13811_CR39","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923 (2011).","journal-title":"N. Engl. J. Med."},{"key":"13811_CR40","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/bjc.2016.45","volume":"114","author":"SM Stein","year":"2016","unstructured":"Stein, S. M. et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br. J. Cancer 114, 737\u2013743. https:\/\/doi.org\/10.1038\/bjc.2016.45 (2016).","journal-title":"Br. J. Cancer"},{"key":"13811_CR41","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/s0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg, Z. A. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial. Lancet 402, 1272\u20131281. https:\/\/doi.org\/10.1016\/s0140-6736(23)01366-1 (2023).","journal-title":"Lancet"},{"key":"13811_CR42","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1245\/s10434-022-11503-6","volume":"29","author":"Y Ushida","year":"2022","unstructured":"Ushida, Y. et al. Optimizing indications for conversion surgery based on analysis of 454 consecutive Japanese cases with unresectable pancreatic cancer who received modified FOLFIRINOX or gemcitabine plus nab-paclitaxel: A single-center retrospective study. Ann. Surg. Oncol. 29, 5038\u20135050. https:\/\/doi.org\/10.1245\/s10434-022-11503-6 (2022).","journal-title":"Ann. Surg. Oncol."},{"key":"13811_CR43","doi-asserted-by":"publisher","first-page":"e1089","DOI":"10.1097\/sla.0000000000005481","volume":"277","author":"T Hank","year":"2023","unstructured":"Hank, T. et al. Oncological outcome of conversion surgery after preoperative chemotherapy for metastatic pancreatic cancer. Ann. Surg. 277, e1089\u2013e1098. https:\/\/doi.org\/10.1097\/sla.0000000000005481 (2023).","journal-title":"Ann. Surg."},{"key":"13811_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051057","author":"Y Mataki","year":"2021","unstructured":"Mataki, Y. et al. Clinical benefits of conversion surgery for unresectable pancreatic ductal adenocarcinoma: A single-institution retrospective analysis. Cancers https:\/\/doi.org\/10.3390\/cancers13051057 (2021).","journal-title":"Cancers"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13811-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13811-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13811-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T03:43:14Z","timestamp":1754710994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13811-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13811"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13811-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This meta-analysis or review article is not applicable to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"28403"}}